Status:
COMPLETED
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects with type 2 diabetes mellitus
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT00097279
Start Date
August 1 2004
End Date
August 1 2005
Last Update
January 11 2017
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35235
2
Novo Nordisk Investigational Site
Glendale, Arizona, United States, 85306
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85006
4
Novo Nordisk Investigational Site
Searcy, Arkansas, United States, 72143